Breast Cancer Index’s Post

Paolo Tarantino, MD, spoke about the most potentially impactful data to come from presentations from ESMO - European Society for Medical Oncology in the breast cancer field. Paolo Tarantino https://lnkd.in/eKWvaVM3 #bcsm #cancer #oncology #ESMO24

MSK researchers Dr. Sandra D'Angelo, Dr. William Tap, and Dr. Michael Offin presented promising studies on treating rare solid tumors, including mesothelioma and three types of soft-tissue tumors, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results of these clinical trials illustrate MSK’s depth and breadth of experience in managing all types of cancer, including those so rare that other doctors may see only a few cases in their whole careers. Learn more about the findings: https://bit.ly/4bGCi4z #ASCO24

BriaCell $BCTX shares unprecedented results at #SABCS2024: -Median OS of 13.4 months in metastatic breast cancer, doubling comparable outcomes -13.7 months OS in CNS metastasis patients -No toxicity-related discontinuations Read more: https://lnkd.in/e-ZkP38N

I am honored to have the opportunity to peer review this paper A complete response on breast MRI could help identify early complete responders in patients who had hormone receptor negative tumours. An imaging-based strategy might limit the duration of chemotherapy in these patients, reduce side-effects, and maintain quality of life if confirmed by the analysis of the 3-year event-free survival primary endpoint. Better monitoring tools are needed for patients with hormone receptor-positive and HER2-positive breast cancer.

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis. #bcsm https://lnkd.in/eNfmvYgc

New release of a Book Chapter as a collaborating author in the eBook entitled, Overcoming Breast Cancer Therapy Resistance From Mechanisms to Precision and AI-Powered Approaches Editor: Zodwa Dlamini The book provides current knowledge and understanding of the challenges associated with drug resistance in breast cancer; discusses the latest advancements in therapeutic approaches for conquering drug resistance in breast cancer; and presents useful knowledge for clinicians and researchers working on breast cancer treatment. https://lnkd.in/esj9bTsW

Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy Frontiers https://lnkd.in/gnRAKHpU

Antibody-drug conjugate datopotamab deruxtecan shows promising activity and a manageable safety profile in patients with advanced breast cancer, according to a study led by our Dr. Funda Meric-Bernstam. Read about this and more research from MD Anderson. #CancerResearch #EndCancer

In this interview with OncLive, Dr. Tara Sanft, MD reviews results from the recently published Decision Impact study, highlighting the importance of the Breast Cancer Index test to help reduce over- and under-treatment. Click here to learn more: https://bit.ly/4aroqdH

The American Society of Clinical Oncology 2024: Breakthroughs in Breast Cancer https://lnkd.in/efY4E_DQ #cancertreatment #cancer #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia